| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 45.9 | 41.6 |
| Gross profit | 16.2 | 5.7 |
| Profit before tax | -24.1 | -45.1 |
| Net income | -13.8 | -25.6 |
| EPS (diluted, $ a share) | $-0.09 | $-0.18 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +10.1% |
|---|---|
| Gross margin | 35.3% |
| Operating margin | -45.0% |
10-Q filed with the SEC, NASDAQ: MRVI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Maravai Lifesciences Holdings, Inc.: key numbers
- Share price
- $7.28Close, Nov 17
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Maravai Lifesciences Holdings, Inc.
All →Maravai Lifesciences Holdings Financial Results
Maravai LifeSciences reported Q3 2026 total revenue of $45.9 million, a 10% increase year-over-year, driven by strong demand for mRNA products and GMP consumables. The company narrowed its net loss to $24.0 million and raised its full-year 2026 revenue and Adjusted EBITDA guidance based on positive momentum in its TriLink and Cygnus segments.
- Term
- Q3 2026
“Our third- quarter results build on the momentum we established in the first half of the year. TriLink revenue grew 12% year-over-year led by 28% revenue growth for our mRNA products, while Cygnus delivered its sixth consecutive quarter of year-over-year growth, with revenue up 8%.”
Bernd Brust, CEO of Maravai LifeSciences
“Four Discovery mRNA customers transitioned to clinical-stage GMP this quarter, reinforcing our belief that today’s Discovery success will create tomorrow’s GMP opportunity. Based on our third-quarter performance and our expectations for the fourth quarter, we are raising our full-year revenue and adjusted EBITDA guidance.”
Bernd Brust, CEO of Maravai LifeSciences